<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    2201888
   </pmid>
   <datecreated>
    <year>
     1990
    </year>
    <month>
     09
    </month>
    <day>
     25
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1990
    </year>
    <month>
     09
    </month>
    <day>
     25
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0025-729X
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       153
      </volume>
      <issue>
       4
      </issue>
      <pubdate>
       <year>
        1990
       </year>
       <month>
        Aug
       </month>
       <day>
        20
       </day>
      </pubdate>
     </journalissue>
     <title>
      The Medical journal of Australia
     </title>
     <isoabbreviation>
      Med. J. Aust.
     </isoabbreviation>
    </journal>
    <articletitle>
     Evening primrose oil and treatment of premenstrual syndrome.
    </articletitle>
    <pagination>
     <medlinepgn>
      189-92
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      The therapeutic effectiveness of evening primrose oil (Efamol, Vita-Glow) in the relief of 10 symptoms associated with premenstrual syndrome (PMS) as well as menstrual symptoms was studied in 38 women. The prospective trial was randomised, double-blind and placebo-controlled and was crossed-over after three cycles. Although the results showed an improvement in symptoms of PMS during the trial, no significant differences in the scoring between the active and placebo groups were found over six cycles. No "carry-over" effect of active medication was observed; the beneficial effect on all symptoms (psychological, fluid retention, breast) was rapid, the scores decreasing in the first cycle but increasing slightly at the change-over period after the third cycle, irrespective of whether the active or placebo medication was next given. These findings indicate that the improvement experienced by these women with moderate PMS was solely a placebo effect.
     </abstracttext>
    </abstract>
    <affiliation>
     University of Queensland, Department of Obstetrics and Gynaecology, Royal Brisbane Hospital, Herston.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Khoo
      </lastname>
      <forename>
       S K
      </forename>
      <initials>
       SK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Munro
      </lastname>
      <forename>
       C
      </forename>
      <initials>
       C
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Battistutta
      </lastname>
      <forename>
       D
      </forename>
      <initials>
       D
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     AUSTRALIA
    </country>
    <medlineta>
     Med J Aust
    </medlineta>
    <nlmuniqueid>
     0400714
    </nlmuniqueid>
    <issnlinking>
     0025-729X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Fatty Acids, Essential
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Linoleic Acids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Plant Oils
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      506-26-3
     </registrynumber>
     <nameofsubstance>
      gamma-Linolenic Acid
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      65546-85-2
     </registrynumber>
     <nameofsubstance>
      Efamol
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Med J Aust. 1990 Nov 19;153(10):630-1
     </refsource>
     <pmid version="1">
      2233440
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Fatty Acids, Essential
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Linoleic Acids
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Placebo Effect
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Plant Oils
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Premenstrual Syndrome
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      psychology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Randomized Controlled Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Statistics as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      gamma-Linolenic Acid
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1990
     </year>
     <month>
      8
     </month>
     <day>
      20
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1990
     </year>
     <month>
      8
     </month>
     <day>
      20
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1990
     </year>
     <month>
      8
     </month>
     <day>
      20
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     2201888
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

